Is there a potential role for protein-conjugate pneumococcal vaccine in older adults?

Australasian Medical Journal

Volumn 5, Issue 4, 2012, Pages 231-235

  Ridda, Iman ^a,b   Musher, Daniel M ^c,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; EDITORIAL; HUMAN; PNEUMOCOCCAL INFECTION; UNITED KINGDOM; VACCINATION;

EID: 84930479362     PISSN: None     EISSN: 18361935     Source Type: Journal    
DOI: 10.4066/AMJ.2012.1160     Document Type: Editorial

References (28)

1. Joint Committee on Vaccination and Immunisation (JCVI). JCVI statements, advice and recommendations. Online. Accessed 2011 on http://www.dh.gov.uk/ab/JCVI/DH_094744. 2011.
2. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report EIPN, Streptococcus pneumoniae, 2009. Online: http://www.cdc.gov/abcs/reportsfindings/surveyreports/spneu09.pdf. Date Accessed September 16, 2011.
3. Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, Zell ER, Linder JA, Grijalva CG, Metlay JP, Finkelstein JA. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29(18):3398-3412.
4. Mandell LA MT, Grossmann RF, Chow AW, Hyland RH. The Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis. 2000;31:383-421.
5. Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis. 2006;42(8):1093-1101.
6. O'Brien KL. Pneumococcal conjugate vaccine, polysaccharide vaccine, or both for adults? We're not there yet. Clin Infect Dis. 2009;49(9):1326-1328.
7. Department Health and Ageing. Therapeutic Goods Administration. TGA issues precautionary advice about Pneumococcal disease vaccine. Online. http://www.tga.gov.au/newsroom/media-2011-pneumovax-110417.htm.
8. Centers for Disease Control and Prevention. Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59(34):1102-1106.
9. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews. 2008(1):CD000422.
10. Koivula I SM, Leinonen M, Makela PH,. Clinical efficacy of pneumococcal vaccine in the elderly a randomized, single-blind population- based trial. Am J Med. 1997;103:281-290.
11. Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, Lindblad I, Sundelof B, and Kalin M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet. 1998;351(9100):399-403.
12. Musher DM MR, Phan HM, Chen G, Baughn RE,. Nonspecificity of assaying for IgG to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia. Clin Infect Dis. 2001;32:534-538.
13. Joint Committee on Vaccination and Immunisation (JCVI). JCVI statement on the routine pneumococcal vaccination programme for adults aged 65 years and older. Online. Accessed on October 2011 on http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_128704.pdf.
14. Aguiar SI, Pinto FR, Nunes S, Serrano I, Melo-Cristino J, Sa-Leao R, Ramirez M and de Lencastre H. Denmark14-230 clone as an increasing cause of pneumococcal infection in Portugal within a background of diverse serotype 19A lineages. J Clin Microbiol. 2010;48(1):101-108.
15. Dortet L, Ploy MC, Poyart C, Raymond J, Ouest ORPIdF. Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagn Microbiol Infect Dis. 2009;65(1):49-57.
16. Pfizer Clinical Trials.gov. Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults (CAPITA). http://clinicaltrials.gov/ct2/show/NCT00744263.
17. French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, Moore M, Antvelink D, Mulder D, Janoff EN, Whitworth J, Gilks CF. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000;355(9221):2106-2111. Epub 2000/07/21.
18. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, Mwaiponya M, Zijlstra E, Molyneux M, and Gilks C. A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. New Engl J Med. 2010;362(9):812-822.
19. Greenberg RN, A. Gurtman, R. Frenck, C. Strout, K. U. Janson, D. Jayawardene, D. A. Scott, E. A. Emini, W. C. Gruber, B. Schmoele-Thoma, editor. A phase 3, randomized, active-controlled trial to evaluate the safety, tolerability, and immunogenicity of sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) administered at 1-year intervals in PPSV23-naive adults 60-64 years of age. Abstract #665 Presented at the 49th annual meeting, Infectious Diseases Society of America, Boston, MA, 2011.
20. Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis. 2008;198(7):1019-1027.
21. de Roux A, Schmole-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, Baker SA, Razmpour A, Emini EA, Fernsten PD, Gruber WC, Lockhart S, Burkhardt O, Welte T, Lode HM. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. [Erratum appears in Clin Infect Dis. 2008 May 1;46(9):1488 Note: Schmoele-Thoma, B [corrected to Schmole-Thoma, B]]. Clin Infect Dis. 2008;46(7):1015-1023.
22. Dransfield MT, Nahm MH, Han MK, Harnden S, Criner GJ, Martinez FJ, Scanlon P, Woodruff P, Washko G, Connett J, Anthonisen N, Bailey W and for the COPD Clinical Research Network. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(6):499-505.
23. Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R, Miller E. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis. 2009;49(9):1318-1325.
24. Jackson LA, Neuzil KM, Nahm MH, Whitney CG, Yu O, Nelson JC, Starkovich PT, Dunstan M, Carste B, Shay DK, Baggs J, Carlone GM. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2007;25(20):4029-4037.
25. Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, Peters HV, Knutsen B, Hickel J, Parkinson AJ. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. Clin Infect Dis. 2009;49(2):241-248.
26. Peñaranda M, Payeras A, Cambra A, Mila J, Riera M, Group tMPS. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. AIDS. 2010;24(8):1226-1228
27. Ridda I, Macintyre CR, Lindley R, Gao Z, Sullivan JS, Yuan FF, McIntyre P. Immunological responses to pneumococcal vaccine in frail older people. [Erratum appears in Vaccine. 2009 Nov 5;27(47):6649]. Vaccine. 2009;27(10):1628-1636.
28. Scott D, Ruckle J, Dar M, Baker S, Kondoh H, Lockhart S. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatrics International. 2008;50(3):295-299.